Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
2.
World J Urol ; 39(9): 3147-3149, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-743719

ABSTRACT

The COVID-19 pandemic has led to the suspension, termination or alteration of thousands of clinical trials as the health emergency escalated globally. Whilst the rapid suspension of certain clinical trials was necessary to ensure the safety of high-risk or vulnerable trial participants as well as healthcare workers, the long-term ramifications that this delay will have on the field of urologic oncology is unknown. The COVID-19 pandemic has highlighted the need to plan for and implement new strategies to advance our understanding of unmet areas of need in urologic oncology. The COVID-19 pandemic has led to the suspension, termination or alteration of thousands of clinical trials as the health emergency escalated globally. Whilst the rapid suspension of certain clinical trials was necessary to ensure the safety of high-risk or vulnerable trial participants as well as healthcare workers, the long-term ramifications that this delay will have on the field of urologic oncology is unknown. The COVID-19 pandemic has highlighted the need to plan for and implement new strategies to advance our understanding of unmet areas of need in urologic oncology.


Subject(s)
COVID-19 , Clinical Trials as Topic , Medical Oncology , Urology , COVID-19/epidemiology , COVID-19/prevention & control , Change Management , Clinical Trials as Topic/methods , Clinical Trials as Topic/organization & administration , Communicable Disease Control/methods , Early Termination of Clinical Trials/adverse effects , Early Termination of Clinical Trials/statistics & numerical data , Early Termination of Clinical Trials/trends , Humans , Medical Oncology/methods , Medical Oncology/trends , Needs Assessment , SARS-CoV-2 , Urology/methods , Urology/trends , Vulnerable Populations
SELECTION OF CITATIONS
SEARCH DETAIL